Annovis Bio, Inc. (NYSE: ANVS)
$6.7650
-0.0250 ( -1.24% ) 84.0K
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Market Data
Open
$6.7650
Previous close
$6.7900
Volume
84.0K
Market cap
$93.68M
Day range
$6.7500 - $7.0200
52 week range
$4.5300 - $22.4900
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 14 | Nov 12, 2024 |
| 10-q | Quarterly Reports | 63 | Nov 08, 2024 |
| 8-k | 8K-related | 14 | Oct 15, 2024 |
| 8-k | 8K-related | 14 | Sep 30, 2024 |
| 8-k | 8K-related | 14 | Aug 15, 2024 |
| 10-q | Quarterly Reports | 63 | Aug 14, 2024 |
| 8-k | 8K-related | 16 | Aug 06, 2024 |
| 8-k | 8K-related | 14 | Jul 16, 2024 |
| 8-k | 8K-related | 13 | Jul 10, 2024 |
| 4 | Insider transactions | 1 | Jul 03, 2024 |